6797.TWO Taiwan Advanced Nanotech Inc.
- Market cap
- TWD 301M
- P/E
- -
- P/B
- 0.47x
- ROE
- -29.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6797.TWO undervalued?
Graham numberThe Graham number of Taiwan Advanced Nanotech Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Taiwan Advanced Nanotech Inc. fundamental analysis
No fundamental analysis for Taiwan Advanced Nanotech Inc. yet.
Taiwan Advanced Nanotech Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Taiwan Advanced Nanotech Inc.
Taiwan Advanced Nanotech Inc. engages in the development, manufacturing, and sales of various functional nanoparticles and automated nucleic acid extraction equipment in Taiwan. The company provides automated extraction instruments; nucleic acid extraction kit that extracts DNA/RNA from samples of blood, cell, tissue, plant, bacteria, virus, etc.; consumables, such as spin tips and deep well plates; filling line systems; and molecular biology reagents. It also provides OEM/O…
Full company profileTaiwan Advanced Nanotech Inc. financial statements
Taiwan Advanced Nanotech Inc. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 114M | 1.72B | 1.93B | 1.33B | 246M | 198M | 154M |
| Gross Profit | 24.7M | 958M | 1.07B | 650M | -31.1M | -30.1M | -75.8M |
| Operating Income | -45.6M | 797M | 801M | 344M | -261M | -207M | -232M |
| EBITDA | -30.3M | 806M | 879M | 577M | -114M | -73.6M | -117M |
| Net Income | -36.6M | 618M | 626M | 326M | -208M | -191M | -227M |
| EPS | -1.43 | 21 | 20 | 11 | -6.83 | -6.20 | -7.54 |
| Balance Sheet | |||||||
| Total Assets | 235M | 1.88B | 2.20B | 2.33B | 1.79B | 1.38B | 1.25B |
| Total Liabilities | 87.4M | 935M | 924M | 819M | 598M | 369M | 477M |
| Shareholders' Equity | 147M | 948M | 1.27B | 1.48B | 1.19B | 1.01B | 772M |
| Cash & Short-term Investments | 98.3M | 818M | 1.10B | 1.25B | 925M | 687M | 193M |
| Total Debt | 67.4M | 356M | 508M | 434M | 491M | 293M | - |
| Cash Flow | |||||||
| Operating Cash Flow | -24.8M | 703M | 703M | 407M | -317M | -18.8M | -21.0M |
| Capital Expenditure | 12.6M | 128M | 180M | 47.2M | 52.7M | 1.51M | 2.45M |
| Free Cash Flow | -37.5M | 576M | 523M | 359M | -370M | -20.3M | -23.4M |
| Ratios | |||||||
| ROE | -24.8% | 65.2% | 49.1% | 22.0% | -17.4% | -18.9% | -29.3% |
| ROA | -15.6% | 32.8% | 28.5% | 14.0% | -11.6% | -13.8% | -18.1% |
| Net Profit Margin | -32.1% | 36.0% | 32.5% | 24.6% | -84.8% | -96.4% | -146.8% |
| Debt to Equity | 0.46x | 0.38x | 0.40x | 0.29x | 0.41x | 0.29x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Taiwan Advanced Nanotech Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 19, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | TWD 91.4M | 3.00 | - |
| 2022 | TWD 139M | 4.50 | 42.6% |
| 2021 | TWD 295M | 9.29 | 47.1% |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1300:1000 on Jun 24, 2022.
Who owns Taiwan Advanced Nanotech Inc.
Ownership data of Taiwan Advanced Nanotech Inc. is not available yet.
Taiwan Advanced Nanotech Inc. company profile
- Company name
- Taiwan Advanced Nanotech Inc.
- Ticker
- 6797.TWO
- ISIN
- TW0006797004
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Medical Devices
- Fiscal year end
- December
- Address
- No.188, Wenhe Road, Taoyuan City, Taiwan
- Phone
- 886 3 3167 568
- Website
- tanbead.com
About Taiwan Advanced Nanotech Inc.
Taiwan Advanced Nanotech Inc. engages in the development, manufacturing, and sales of various functional nanoparticles and automated nucleic acid extraction equipment in Taiwan. The company provides automated extraction instruments; nucleic acid extraction kit that extracts DNA/RNA from samples of blood, cell, tissue, plant, bacteria, virus, etc.; consumables, such as spin tips and deep well plates; filling line systems; and molecular biology reagents. It also provides OEM/ODM services. The company was founded in 2004 and is based in Taoyuan City, Taiwan.
Taiwan Advanced Nanotech Inc. management
2- Mr. Chien Hsing ChienFounder, CEO, GM & Director
- Zhibao ZhangAccounting Supervisor